Skip to main content

Author Correction: Results of the phase IIa RADICAL trial of the FGFR inhibitor AZD4547 in endocrine resistant breast cancer.

Publication ,  Journal Article
Coombes, RC; Badman, PD; Lozano-Kuehne, JP; Liu, X; Macpherson, IR; Zubairi, I; Baird, RD; Rosenfeld, N; Garcia-Corbacho, J; Cresti, N; Lim, A ...
Published in: Nat Commun
January 17, 2023

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

Nat Commun

DOI

EISSN

2041-1723

Publication Date

January 17, 2023

Volume

14

Issue

1

Start / End Page

260

Location

England
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Coombes, R. C., Badman, P. D., Lozano-Kuehne, J. P., Liu, X., Macpherson, I. R., Zubairi, I., … Seckl, M. J. (2023). Author Correction: Results of the phase IIa RADICAL trial of the FGFR inhibitor AZD4547 in endocrine resistant breast cancer. Nat Commun, 14(1), 260. https://doi.org/10.1038/s41467-023-35969-4
Coombes, R. C., P. D. Badman, J. P. Lozano-Kuehne, X. Liu, I. R. Macpherson, I. Zubairi, R. D. Baird, et al. “Author Correction: Results of the phase IIa RADICAL trial of the FGFR inhibitor AZD4547 in endocrine resistant breast cancer.Nat Commun 14, no. 1 (January 17, 2023): 260. https://doi.org/10.1038/s41467-023-35969-4.
Coombes RC, Badman PD, Lozano-Kuehne JP, Liu X, Macpherson IR, Zubairi I, et al. Author Correction: Results of the phase IIa RADICAL trial of the FGFR inhibitor AZD4547 in endocrine resistant breast cancer. Nat Commun. 2023 Jan 17;14(1):260.
Coombes, R. C., et al. “Author Correction: Results of the phase IIa RADICAL trial of the FGFR inhibitor AZD4547 in endocrine resistant breast cancer.Nat Commun, vol. 14, no. 1, Jan. 2023, p. 260. Pubmed, doi:10.1038/s41467-023-35969-4.
Coombes RC, Badman PD, Lozano-Kuehne JP, Liu X, Macpherson IR, Zubairi I, Baird RD, Rosenfeld N, Garcia-Corbacho J, Cresti N, Plummer R, Armstrong A, Allerton R, Landers D, Nicholas H, McLellan L, Lim A, Mouliere F, Pardo OE, Ferguson V, Seckl MJ. Author Correction: Results of the phase IIa RADICAL trial of the FGFR inhibitor AZD4547 in endocrine resistant breast cancer. Nat Commun. 2023 Jan 17;14(1):260.

Published In

Nat Commun

DOI

EISSN

2041-1723

Publication Date

January 17, 2023

Volume

14

Issue

1

Start / End Page

260

Location

England